Company intelligence / Profile preview

Lupus Therapeutics

New York City/New York, New York, United Stateslupustherapeutics.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Lupus Therapeutics has enabled over 10 active clinical trials through its LuCIN network since its founding in 2017. It collaborates with biopharma companies to accelerate the development and testing of new therapies for lupus. The organization focuses on improving trial access, diversity in enrollment, and patient-centric research design. It does not sponsor or own drug assets but provides infrastructure and expertise to advance external sponsors’ programs.

Therapeutic areas: Immunology
Industry: Contract Research Organization

Partnerships

At least nine pharmaceutical/biotech partnerships including collaborations with major industry sponsors running SLE/lupus trials at LuCIN centers

Beyond the preview

Go deeper on Lupus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lupus Therapeutics.

Explore the full profile